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Abstract
Some studies found that providing micronutrient powder (MNP) causes adverse health outcomes, but modifying factors are unknown. We aimed
to investigate whether Fe status and inherited Hb disorders (IHbD) modify the impact of MNP on growth and diarrhoea among young Lao
children. In a double-blind controlled trial, 1704 children of age 6–23 months were randomised to daily MNP (with 6 mg Fe plus fourteen micronutrients) or placebo for about 36 weeks. IHbD, and baseline and final Hb, Fe status and anthropometrics were assessed. Caregivers provided
weekly morbidity reports. At enrolment, 55·6 % were anaemic; only 39·3 % had no sign of clinically significant IHbD. MNP had no overall impact
on growth and longitudinal diarrhoea prevalence. Baseline Hb modified the effect of MNP on length-for-age (LAZ) (P for interaction = 0·082).
Among children who were initially non-anaemic, the final mean LAZ in the MNP group was slightly lower (–1·93 (95 % CI –1·88,
–1·97)) v. placebo (–1·88 (95 % CI –1·83, –1·92)), and the opposite occurred among initially anaemic children (final mean LAZ –1·90 (95 % CI
–1·86, –1·94) in MNP v. –1·92 (95 % CI –1·88, –1·96) in placebo). IHbD modified the effect on diarrhoea prevalence (P = 0·095). Among children
with IHbD, the MNP group had higher diarrhoea prevalence (1·37 (95 % CI 1·17, 1·59) v. 1·21 (95 % CI 1·04, 1·41)), while it was lower among
children without IHbD who received MNP (1·15 (95 % CI 0·95, 1·39) v. 1·37 (95 % CI 1·13, 1·64)). In conclusion, there was a small adverse effect of
MNP on growth among non-anaemic children and on diarrhoea prevalence among children with IHbD.
Key words: Micronutrient powder: Young children: Inherited Hb disorder: Iron status: Anaemia: Growth: Diarrhoea

Anaemia and deficiencies of Fe, iodine, Zn and vitamin A remain
public health concerns in many low-income countries(1).
Multiple micronutrient powder (MNP) can be used for pointof-use fortification of foods consumed by young children and
are recommended by the WHO to improve Fe status and reduce
anaemia among children 6–23 months of age in populations
where anaemia is a public health problem(2). While the evidence
for the positive impact of MNP on anaemia and Fe deficiency is
consistent(3,4), two recent meta-analyses of MNP reached different conclusions regarding morbidity outcomes. De Regil et al.(3)
found no effect of MNP on diarrhoea (risk ratio 0·97, 95 % CI

0·53, 1·78)), whereas Salam et al.(4) found an increased risk in
diarrhoea incidence with MNP (risk ratio 1·04, 95 % CI 1·01,
1·06). Indeed there has been emerging evidence that an
increased risk of infection, particularly from diarrhoea and
malaria in areas of high transmission, may be associated with
Fe supplementation(5). For young children, WHO recommends
MNP containing 10–12·5 mg of elemental Fe, 300 μg retinol and
5 mg of elemental Zn per sachet, with or without other
micronutrients, and the provision of ninety sachets for consumption over a 6-month period(2), though many programmes
provide daily doses(6). To ensure safety, the WHO recommends

Abbreviations: IHbD, inherited Hb disorders; Lao PDR, Lao People’s Democratic Republic; LAZ, length-for-age z score; MNP, micronutrient powder; MUAC,
mid-upper arm circumference; MUACZ, MUAC z score; SQ-LNS, small quantity lipid-based nutrient supplements; sTfR, soluble transferrin receptor; WLF,
weight-for-length z score.
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that MNP programmes also include behaviour change strategies
to promote appropriate breastfeeding and complementary feeding practices, handwashing with soap, prompt attention to fever
in malaria-endemic settings and measures to manage diarrhoea(2). However, further research is needed to find safe ways
of providing Fe-containing MNP.
Inherited Hb disorders (IHbD), consisting of structural Hb
variants and thalassaemia, are found worldwide. The symptoms
and clinical relevance of IHbD vary with the type and severity of
the genetic defect and their effect on Hb structure and function.
For example, β-thalassaemia is caused by partial or complete
absence of β-globin synthesis due to mutations that affect
transcription, translation and mRNA processing as well as
gene deletion(7). In Southeast Asia, severe Hb disorders include
α0-thalassaemia, β0-thalassaemia, β-thalassaemia-Hb E disease
and Hb H disease, all of which are associated with acute and
chronic complications and serious health problems(8,9). In
addition, a large percentage of the population in Southeast
Asia has non-severe IHbD, such as the α-thalassaemia trait
(20–30 %), the β-thalassaemia trait (3–9 %) and the Hb E trait
(up to 60 %)(8,10). These latter milder forms of IHbD result from
deletions or mutations in one or more, but not all, of the α- or
β-globin alleles and often lead to only mild microcytosis, with
or without anaemia(11). A study of young Cambodian children
found that homozygous Hb E was associated with an eighteen
times higher risk of anaemia, and other heterozygous mutations
were associated with a small but highly significant increased
anaemia risk(12). This latter study also found that heterozygous
and homozygous Hb E, with or without α-thalassaemia trait,
increased plasma ferritin and soluble transferrin receptor
(sTfR) concentrations likely due to ineffective erythropoiesis
and/or increased Fe absorption. Provision of supplementary
Fe in foods may be contraindicated for some individuals with
IHbD, as Fe absorption may not be normally regulated(13–15).
Thus, there is a risk that the insufficient down-regulation of Fe
absorption in Fe-replete individuals with asymptomatic types
of IHbD, which are prevalent in the populations of Southeast
Asia, may cause adverse health outcomes when consuming
supplementary Fe in products like MNP.
In view of these concerns about potential adverse effects of
MNP on growth and morbidity in some populations(4,5), and
separate concerns raised about providing Fe to individuals with
IHbD(13,14), we tested a new MNP formulation, which contained
a lower amount of Fe (6 mg/daily dose) and a higher amount of
Zn (10 mg) than current formulations, along with thirteen
other micronutrients. Main study outcomes are presented elsewhere(16). Briefly, despite improving plasma Zn concentration,
the provision of MNP had no impact on linear growth and the
prevalence of diarrhoea and acute respiratory tract infections(16,17).
MNP improved the overall Fe status but tended to reduce anaemia
only among children who were anaemic at baseline(16).
The objectives of the present analyses were to (1) explore
associations between IHbD and anaemia, micronutrient and
growth status and morbidity burden; (2) explore whether the
effects of a low-Fe-containing MNP on Fe status are modified
by baseline Fe status and IHbD type; and (3) investigate whether
baseline anaemia and Fe status and IHbD are potential risk factors for adverse effects of MNP on linear growth and morbidity.

We hypothesised that children with IHbD who receive MNP
would have a smaller increase in Hb concentration and a greater
increase in ferritin concentration than children without IHbD.
Considering the reduced Fe content of the MNP, we further
hypothesised that the product would be safe for all children
participating in the study and that there would be no adverse
impact of the intervention on growth and diarrhoea regardless
of the baseline Fe status or presence of IHbD.

Methods
Study design and participants
The Lao Zinc study was designed as a randomised, double-blind
controlled intervention trial. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human subjects were
approved by the National Ethics Committee for Health
Research, Ministry of Health, Lao People’s Democratic Republic
(PDR; reference 039/NECHR), and the institutional review boards
of the University of California, Davis, USA (reference 626187) and
Khon Kaen University, Khon Kaen, Thailand (reference
HE592006). Parental written informed consent was obtained from
all subjects. The trial is registered as the Lao Zinc Study,
NCT02428647 (https://clinicaltrials.gov). The trial was conducted
from September 2015 to April 2017 in rural areas of
Khammouane Province in Lao PDR.
The primary objective of the parent study was to determine
the effects of two forms of daily preventive Zn supplementation
v. therapeutic Zn supplementation for diarrhoea on young children’s physical growth and other health outcomes(16).
The study procedures are described in detail elsewhere(18).
Briefly, written, informed consent was obtained by signature
or fingerprint from one of the child’s primary caregivers (mother,
father or legal guardian). In case the caregiver was illiterate, an
impartial witness was present during the consent process, who
confirmed that the information in the consent document was
accurately explained to the participant and that the consent
was freely given. Children were considered eligible if they were
6–23 months of age, their families accepted weekly home visits,
planned to remain within the study area for the duration of the
study and signed the informed consent document. Children were
ineligible if they met one of the following criteria: severe anaemia (Hb < 70 g/l), weight-for-length z score (WLZ) < –3 SD(19),
presence of bipedal oedema, severe illness warranting hospital
referral, congenital abnormalities potentially interfering with
growth, chronic medical conditions (e.g. malignancy) requiring
frequent medical attention, known HIV infection of the index
child or the child’s mother, currently consuming Zn supplements
or currently participating in any other clinical trial. A total of 3433
infants and young children 6–23 months of age were enrolled
and individually randomised to one of four intervention groups
using a computer-generated block randomisation scheme, with
randomly selected block lengths of four or eight. The randomisation scheme was generated by a UC Davis statistician, and
the study field workers assigned children following a list of study
identification numbers. For the present analyses, only children
randomised to the following two groups are considered: (1)
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the MNP group who received a daily preventive MNP containing
6 mg Fe, 10 mg Zn and thirteen other micronutrients or (2) the
placebo control group who received daily placebo powder. The
intervention products were distributed weekly for about 36
weeks. Both groups received low-osmolarity oral rehydration salt
(ORS) solution for diarrhoea treatment. ORS was part of the diarrhoea treatment kit, which was given during enrolment, with
instructions to store it in the home and use it for the treatment
of a diarrhoea episode in the study child.

Randomisation, masking and intervention products
The MNP and placebo powder sachets were produced by DSM
Fortitech Asia Pacific (Banting, Malaysia). One MNP sachet provided the following micronutrients daily: 400 μg retinol activity
equivalents (RAE) vitamin A, 0·5 mg thiamine, 0·5 mg riboflavin,
6 mg niacin, 0·5 mg vitamin B6, 150 μg dietary folate equivalents
(DFE) folic acid, 0·9 μg cyanocobalamin, 30 mg ascorbic acid,
5 mg cholecalciferol, 5 mg tocopherol equivalents (TE) DL-αtocopheryl acetate, 0·56 mg Cu as copper sulphate anhydrous,
90 μg iodine as potassium iodate, 6 mg Fe as ferrous fumarate,
17 μg Se as selenium selenite and 10 mg Zn as zinc gluconate.
To ensure masking of the four intervention groups in the parent
study(18), all groups received a therapeutic tablet in case of
diarrhoea, which were placebo tablets for the MNP and the placebo
groups (produced by Nutriset SAS, Malaunay, France). To ensure
blinding of investigators, study field staff and participating families,
all intervention products were coded with a two-digit group code
and a group-specific colour. Caregivers were instructed to add the
entire content of the powder package into a single serving of semisolid or mashed food after the food had been cooked and cooled
sufficiently to be eaten (but within 30 min of preparation).
Caregivers were encouraged to mix the powder package into suitable foods such as mashed mango, banana and papaya, boiled
pumpkin and boiled egg(20).

Procedures
To assess eligibility, children’s length, weight and mid-upper arm
circumference (MUAC) were measured and Hb concentration
was determined in a capillary blood sample (HemoCue®
Hb301; HemoCue AB). Maternal and household demographic
and socio-economic characteristics of eligible children were
recorded. Household food security was assessed using the
Household Food Insecurity Access Scale(21). Children’s
anthropometric assessments were repeated after 36 weeks
(end line). Unclothed or lightly dressed children were weighed
to the nearest 20 g (SECA 383). Children’s recumbent length
(SECA 416) and MUAC (left arm; Tri-Colored Single-Slotted
Insertion Tape, Weigh and Measure) were measured to the nearest 0·1 cm. All measurements were collected in duplicate and the
average of the two measurements was calculated. If measurements differed by >0·1 kg (weight), or >0·5 cm (length,
MUAC), the measurement was repeated a third time and the
average of the two closest measurements was calculated.
Maternal weight (SECA 874) and height (SECA 213) were
assessed once over the course of the study using a similar
approach. Regular standardisation sessions were implemented
to compare the performance of anthropometry teams among
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themselves and with their supervisors(22); results of these standardisations have been reported previously(16,23).
Children were visited weekly for delivery of intervention
products and completion of a systematic, symptom-based, morbidity recall history, using a standardised data collection form.
Specifically, caregivers reported stool number and consistency,
among other symptoms during the preceding 7 d. Caregivers
were instructed to initiate diarrhoea treatment (with ORS) whenever a child had >3 liquid or semi-liquid stools within a 24-h
period. In addition, the morbidity surveillance worker reminded
the caregiver to start or continue diarrhoea treatment as needed.
If a child had persistent diarrhoea (>14 d), 20 mg Zn/d was
provided for 10 d regardless of group assignment. Child feeding
practices were assessed every 4 weeks with a brief FFQ to calculate selected WHO infant and young child feeding (IYCF) indicators, such as dietary diversity and minimum meal frequency(24,25).
At baseline and end line, a venous blood sample was collected
from children who were not acutely ill. The blood was first collected into an evacuated, trace element-free 7·5 ml polyethylene
blood collection tube containing lithium heparin and, if adequate
blood was available, into an evacuated 1·2 ml polyethylene blood
collection tube containing EDTA (Sarstedt AG & Co.; reference
01.1604.400 and 06.1666.100, respectively). The blood samples
were stored at 4–8°C and transported to the field project laboratory. The heparinised blood was centrifuged within 8 h of collection at 1097 g (3100 rpm) for 10 min (PowerSpin Centrifuge Model
LX C856; United Products & Instruments, Inc.). Plasma was aliquoted into 0·2 ml pre-labelled microcentrifuge tubes and stored
at –20°C. Heparinised plasma samples were shipped on dry ice
and remained frozen until analyses at the VitMin Lab
(Willstaett, Germany) where ferritin, sTfR, C-reactive protein
and α-1-acid glycoprotein concentrations were determined using
a combined sandwich ELISA technique(26).
The EDTA blood samples were collected at baseline for IHbD
typing. These samples were transported to Thailand for detection
of IHbD using an automated capillary zone electrophoresis
(Capillarys II; Sebia) at Nakhon Phanom Hospital and PCR techniques at Khon Kaen University(27,28). The types and levels of
the following Hb fractions were determined: normal Hb (A, A2, F)
and Hb variants (E and Constant Spring (CS)). Identification of
α0-thalassaemia genes, including SEA and THAI deletions, was
completed in all cases. Molecular screening for β-thalassaemia
mutations was carried out in cases with either Hb A2 > 3·5 % or
Hb EF phenotype. We determined the homozygosity of the Hb
E phenotypes. In cases where no EDTA blood specimen was collected at baseline, we attempted to collect an EDTA blood sample
at end line for IHbD typing.

Definitions and expression of results
Anaemia and Fe deficiency were defined based on the
following cut-offs: anaemia: Hb < 110 g/l; and Fe deficiency:
ferritin < 12 μg/l and/or sTfR > 8·3 mg/l.
Length-for-age (LAZ), weight-for-age (WAZ), WLZ and MUAC
(MUACZ) z scores were calculated according to the WHO 2006
growth standards(19,29). Stunting, underweight and wasting were
defined as < –2 SD LAZ, WAZ and WLZ, respectively. Diarrhoea
was defined as the presence of ≥3 loose or liquid stools per 24 h.
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Table 1. Definitions of inherited Hb disorders (IHbD)
Definition based on Hb type and genetic results

IHbD type

Presence/absence of IHbD

A2A or CSA2A, Hb A2 ≤ 3·5%
Negative α0-thalassaemia gene

Non-IHbD or non-clinically significant
IHbD

Non-IHbD or non-clinically significant
IHbD

A2A, Hb A2 ≤ 3·5%
Positive α0-thalassaemia gene

α0-Thalassaemia trait

Clinically significant IHbD

EA, Hb E < Hb A
Positive α0-thalassaemia gene

α0-Thalassaemia trait

Clinically significant IHbD

EA or CSEA, Hb E < Hb A
Negative α0-thalassaemia gene

Hb E trait

Clinically significant IHbD

A2A, Hb A2 > 3·5 %
Negative α0-thalassaemia gene

β-Thalassaemia trait or homozygous
Hb E

Clinically significant IHbD

EE or CSEE, EF or CSEF (with positive testing for Hb E
homozygote)
Either negative or positive α0-thalassaemia gene

β-Thalassaemia trait or homozygous
Hb E

Clinically significant IHbD

α-Thalassaemia disease: A2ABart’sH or CSA2ABart’sH
Hb E/β-thalassaemia disease: EF, EFA (with Hb E > Hb A)
αβ-Thalassaemia disease:
EABart’s or CSEABart’s
EEBart’s or CSEEBart’s
EFBart’s or CSEFBart’s
All cases were confirmed by DNA analysis

Thalassaemia disease

Clinically significant IHbD

CS, Constant Spring.

Primary outcomes of the present analyses were the concentrations of Hb, ferritin and sTfR, length, weight, LAZ, WAZ and WLZ
and diarrhoea prevalence; and secondary outcomes focused on
the prevalence of anaemia, low ferritin, high sTfR, stunting, underweight and wasting. To investigate the modifying effects of IHbD
on these outcomes, IHbD types were categorised based on Hb
type and genetic results. All children with normal Hb type
(A2A; Hb A2 ≤ 3·5 %, with negative PCR analysis for α0-thalassaemia) were classified as non-IHbD or non-clinically significant
IHbD. Children with normal Hb type with positive results
for an α0-thalassaemia gene mutation were categorised as
α0-thalassaemia trait. The β-thalassaemia trait was diagnosed in
cases with Hb A2 > 3·5 %. Homozygous Hb E was defined based
on homozygosity testing. Thalassaemia disease was diagnosed in
children with abnormal Hb profiles (A2ABart’sH, CSA2ABart’sH,
EABart’s, CSEABart’s, EEBart’s, CSEEBart’s, EFBart’s, CSEFBart’s,
EF, EFA) and/or as indicated by a complete analysis of α- and
β-thalassaemia genes. To achieve adequate sample size, we
combined the IHbD types into five categories (non-IHbD or
non-clinically significant IHbD, α0-thalassaemia trait, β-thalassaemia trait or homozygous Hb E, Hb E trait and α- or HbE/β- or
αβ-thalassaemia disease; Table 1) henceforth referred to as IHbD
types. We further combined all IHbD into one category (the clinically significant IHbD, comprising α0-thalassaemia trait, Hb E trait,
β-thalassaemia trait or homozygous Hb E or thalassaemia disease)
and compared against all cases without clinically significant IHbD.
Although the health consequences of Hb E trait are generally mild,
this group was included in the ‘clinically significant IHbD’ group
due to its high prevalence in the study population and thus the
potential relevance for public health programmes, considering
the distribution of MNP.

Sample size
Because objectives 2 and 3 of the present analyses were to examine the potential modifying effects of Fe status and IHbD on
response to MNP, the sample size for the present analyses was
based on the full sample size available for the MNP and the placebo groups in the parent study. As described previously(18), a
total of 710 children were needed in each of the treatment groups.
Allowing for 15 % attrition, we needed to enrol 835 children per
group, which we rounded up to 850 per group. For the present
two-group analyses, this would allow the detection of an effect
size of 0·18 (α = 0·05, β = 0·10) for the main outcomes (anaemia,
Fe status, growth and morbidity), and the detection of a difference
in effect size of about 0·35 (α = 0·05, β = 0·10) for the modifying
effect of baseline Fe status or IHbD on the main effects.

Statistical analyses
A statistical analysis plan was posted online prior to commencing
data analyses(30). Primary analyses were performed using R version
3.4. Treatment effects were assessed in minimally adjusted models
including baseline measurement (if collected), age of the child at
enrolment and district of enrolment. Treatment effects were
assessed at the 5 % level of significance. In secondary analyses,
we created adjusted models that included covariates strongly associated with the outcome to potentially improve the precision of our
estimates (i.e. decrease standard errors). We considered a list of
pre-specified covariates for inclusion if they were associated with
the outcome at a 10 % significance level in bivariate analyses.
ANCOVA models were used to assess continuous
anthropometry outcomes, Hb concentration and log transformed Fe status indicators, while modified Poisson regression

Downloaded from https://www.cambridge.org/core. Missouri State University, on 07 May 2021 at 17:39:14, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114519001715

898

was used to assess all dichotomous outcomes. Negative binomial
models with an offset were used for the morbidity outcomes.
A pre-specified list of effect modifiers was assessed by including
an interaction term in the minimally adjusted models. Marginally
significant interactions (P < 0·1) were further examined with
stratified analyses, estimation of separate regression lines or
estimation of adjusted means at certain values of the effect modifier,
in order to understand the nature of the effect modification. For
illustrative purposes, we present figures of the stratified analyses
for outcomes with significant or marginally significant effect
modifications.
Baseline measures were compared across IHbD groups by
testing the global null hypothesis of any differences by group
using a likelihood ratio test, controlling for child’s age at enrolment
and district of residence. Group estimates were then qualitatively
assessed to describe clinically meaningful patterns across groups.
Both Fe status indicators (plasma ferritin, sTfR) were adjusted
for inflammation by adapting procedures recommended
by the Biomarkers Reflecting Inflammation and Nutritional
Determinants of Anemia (BRINDA) group(31,32). Specifically,
adjustment factors reflecting the changes in nutritional biomarkers during inflammation were determined by pooling
together the samples collected at baseline from all four intervention groups of the Lao Zinc Study(16). The adjustment factors
(i.e. regression coefficient for C-reactive protein and/or α-1-acid
glycoprotein) were subsequently applied to both baseline and
end line samples. In adapting the BRINDA approach, we used
the 10th percentile of the C-reactive protein and α-1-acid glycoprotein concentrations in this population as a cut-off for determining whether adjustment was necessary. Only inflammationadjusted Fe status results will be presented here.

Results
Baseline characteristics of study population
A total of 3830 children were screened for eligibility for the parent
study, and 3433 were enrolled and assigned to one of the four
intervention groups, of which 852 were assigned to the MNP
and placebo control groups. The final sample size included in
the present analyses depended on the specific outcome
(Fig. 1). Attrition was similar across intervention groups, with
the largest difference between groups occurring for end line
anthropometry where MNP had 82·3 % and placebo had 86·9 %
follow-up, which resulted in a difference of 4·6 %. Reasons for loss
appear to be similar across intervention arms. The most common
recorded reasons were ‘withdrawal with no reason provided’
making up 52·9 % and ‘moving’ making up 27·0 %. MNP had a
higher rate of withdrawal due to vomiting (n 19, 12·6 % of
MNP withdrawals compared with n 2, 1·8 % of placebo withdrawals). When comparing the baseline characteristics of children with
end line anthropometric outcomes, there were no significant
differences among the two groups (Supplementary Table S1).
Among children enrolled in the two groups (n 1704), 1336 provided a venous blood sample at baseline for assessment of Fe status, and IHbD was assessed in 1412 children.
The mean age of children at enrolment was 14·2 (SD 5·0)
months and the mean age of their mothers was 26·9 (SD 6·0) years
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(Table 2). Reported IYCF practices at baseline indicated that only
15·3 % had adequate dietary diversity, but more than half
reported achieving minimum meal frequency and consumption
of Fe-rich foods (59·1 and 66·7 %, respectively). These indicators
of IYCF improved somewhat over the course of the study, but
adequate dietary diversity was still only reported on about a third
of observation days.
Approximately one-third of the children (39·3 %) had no evidence of a clinically significant IHbD, 2·8 % had α0-thalassaemia
trait, 42·7 % had Hb E trait, 13·4 % had β-thalassaemia trait or were
homozygous for Hb E and 1·8 % had α- or β-thalassaemia disease
(Table 1). Overall anaemia prevalence was 55·6 % at baseline. All
children with thalassaemia disease were anaemic, and three
fourths of the children with α0-thalassaemia trait, β-thalassaemia
trait and homozygous Hb E were anaemic compared with an
anaemia prevalence of 46·8 % among children without clinically
significant IHbD (P < 0·001; Table 3). Ferritin marginally differed
by IHbD group with higher concentrations among children with
any type of IHbD compared with those without. High sTfR status
was more common among children with α0-thalassaemia trait,
β-thalassaemia trait or homozygous Hb E and α- or β-thalassaemia
disease (63·6 to 100 %) than among those without IHbD (53·3–
56·1 %). LAZ at baseline and prevalence of underweight also significantly differed by IHbD group, with α- or β-thalassaemia diseased children having lower LAZ (–2·1 v. roughly –1·7) and higher
prevalence of underweight (42·3 v. roughly 25 %; Table 3).

Effects of micronutrient powder on children’s Hb and iron
status and effect modification by baseline Hb and iron
status and inherited Hb disorders
Overall, MNP significantly increased Hb concentration compared
with placebo(16) (Supplementary Table S2). However, this resulted
in only a marginally lower final anaemia prevalence among children who received MNP (39·7 %) compared with children in the
placebo group (43·2 %; P = 0·067). Children in the MNP group
had a significantly greater increase in ferritin and a reduction in
sTfR concentrations compared with those in the placebo group.
At end line, 20·3 % children in the MNP group had low ferritin compared with 30·7 % in the placebo group (P < 0·001). Similarly, the
prevalence of elevated sTfR was lower in the MNP group compared with the placebo group (45·2 v. 53·3 %; P = 0·006).
We tested for effect modification of baseline Hb and Fe
status and IHbD on the impact of MNP on Hb, anaemia, Fe status
and Fe deficiency (Table 4). The impact of MNP on end line Hb
was significantly modified by baseline Hb and ferritin concentrations (P for interaction = 0·037 and 0·012, respectively; Fig. 2).
Specifically, children who were anaemic at baseline had a
greater Hb response to MNP than placebo, but there was no difference in the Hb response among non-anaemic children.
Likewise the effects of MNP on ferritin and sTfR concentrations
at end line were both significantly greater among children who
were Fe deficient at baseline.
As mentioned above, the modifying effect of IHbD was
explored by considering both the five IHbD types and the presence/absence of clinically significant IHbD. Neither the IHbD
type nor the presence/absence of IHbD modified the impact of
MNP on Hb, ferritin and sTfR concentrations at end line
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Fig. 1. Flow chart of study participants. * The main trial included four intervention groups; only two of these are included in the present analysis, for which details are
shown here. MNP, micronutrient powder; IHbD, inherited Hb disorders.

(Fig. 3). In addition, the presence/absence of IHbD did not
modify the impact of MNP on the prevalence of anaemia at
end line. However, there was a marginally significant modifying
effect of the presence/absence of IHbD on the effect of MNP on
the prevalence of low ferritin and high sTfR concentrations at end
line (P for interaction = 0·062 and 0·062, respectively). In particular, among children in the placebo group, those with clinically significant IHbD had a lower final prevalence of Fe deficiency
(based on low ferritin) than those without clinically significant
IHbD (26·5 (95 % CI 22·2, 30·9) %) v. 35·8 (95 % CI 30·4,
41·3) %). In the MNP group, there was a greater response to
MNP among those without IHbD. This resulted in a final prevalence of Fe deficiency (based on low ferritin), which was the same
in both sets of children who received MNP, regardless of their
IHbD status (20·9 (95 % CI 15·4, 26·4) % v. 20·1 (95 % CI 15·8,

24·5) %). A similar pattern was seen with regard to the final prevalence of elevated sTfR. The impact of MNP on the prevalence of
high sTfR was largest among children without clinically significant
IHbD (41·5 (95 % CI 35·6, 47·3) %), compared with children with
IHbD (47·2 (95 % CI 42·5, 51·8) %). In comparison, children in the
placebo group had a slightly higher prevalence of elevated sTfR
(54·1 (95 % CI 48·3, 59·9) %) among those without clinically significant IHbD v. those with IHbD (51·7 (95 % CI 47·1, 56·3) %).
Because the models did not converge to assess the modifying
effect of IHbD type on the final prevalence of anaemia, low ferritin and high sTfR (Table 4), we investigated the impact of MNP on
these prevalence in stratified analyses by those IHbD types with
adequately large sample sizes (non-clinically significant IHbD, n
475; Hb E trait, n 530; β-thalassaemia trait or homozygous Hb E, n
167). The impact of MNP on anaemia prevalence at end line was
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Table 2. Baseline characteristics of young children, mothers and households
(Mean values and standard deviations; numbers of participants; percentages)
All
Mean
n
Children
Enrolment age (months)
Male (%)
Adequate dietary diversity at baseline* (%)
Minimum meal frequency at baseline* (%)
Consumption of Fe-rich foods at baseline* (%)
Proportion of days with adequate dietary diversity†
Proportion of days with minimum meal frequency†
Proportion of days with Fe-rich foods†‡
Mothers
Age (years)
Maternal height (cm)
Maternal BMI (kg/m2)
Years of education
Buddhist (%)
Married (%)
Households
Food secure§ (%)
Number of children under 5 years
Improved walls and floor (%)
Number of rooms
Number of poultry owned

MNP
SD

Mean

1704
14·2

Placebo
SD

Mean

852
5·0

14·2

50·4
15·3
59·1
66·7

SD

852
5·0

14·1

49·5
14·1
60·3
66·9

5·1
51·3
16·5
58·0
66·5

0·30
0·62
0·85

0·28
0·36
0·20

0·30
0·61
0·85

0·28
0·36
0·19

0·29
0·62
0·84

0·28
0·35
0·20

26·9
150·6
21·4
4·6

6·0
5·2
2·9
3·5

26·9
150·5
21·4
4·7

5·9
5·1
2·9
3·5

27·0
150·7
21·4
4·6

6·2
5·3
3·0
3·5

89·1
95·7

88·2
96·4

34·2
1·5

34·4
0·7

1·4

31·9
2·5
9·3

90·1
94·9
34·0
0·6

1·5

32·0
1·0
11·1

2·5
9·2

0·7
31·8

1·0
10·9

2·5
9·5

1·0
11·2

MNP, micronutrient powder; IYCF, infant and young child feeding.
* Baseline IYCF practices during 24 h prior to enrolment(24,25).
† IYCF practices assessed every 4 weeks throughout the study; proportion of observed days with the positive feeding behaviour during study.
‡ Fe-rich foods did not include the MNP provided by the study.
§ Food security assessed using the Household Food Insecurity Access Scale(21).

not modified by the IHbD type, and the prevalence of Fe deficiency
(low ferritin and high STfR) was significantly reduced only in children without clinically significant IHbD (Table 5). We were unable
to draw conclusions regarding the modifying effects of α0-thalassaemia trait and α ‐ or β-thalassaemia disease on the prevalence
of anaemia and Fe deficiency due to the small sample size of these
IHbD subgroups.

Effects of micronutrient powder on children’s growth and
effect modification by baseline iron status and inherited
Hb disorders
Overall, MNP had no impact on any of the growth outcomes at
end line compared with placebo(16) (Supplementary Table S3).
The impact of MNP on some growth outcomes (LAZ, MUAC,
MUACZ) was modified by baseline Hb (Fig. 4), but not Fe status
(Table 4). There was an adverse effect of MNP on some
growth outcomes among non-anaemic children, as the
final mean LAZ in the MNP group was slightly lower (–1·93
(95 % CI –1·88, –1·97)) v. the placebo group (–1·88 (95 %
CI–1·83, –1·92); P for interaction = 0·082); similarly, the final
mean MUAC was slightly smaller in the MNP group (14·01
(95 % CI 13·94, 14·07) cm) v. the placebo group (14·05 (95 %
CI 13·99, 14·11) cm; P for interaction = 0·038). On the other
hand, among the initially anaemic children, there was a tendency of a potential beneficial impact, though the magnitude
was very small on the final mean LAZ (–1·90 (95 % CI –1·86,
–1·94) in MNP v. –1·92 (95 % CI –1·88, –1·96) in placebo) and
the final mean MUAC (13·98 (95 % CI 13·92, 14·03) cm in
MNP v. 13·96 (95 % CI 13·91, 14·02) cm in placebo). The

presence/absence of IHbD did not modify the effect of MNP
on growth, except for wasting (P for interaction = 0·019; Fig. 4).
Among children with IHbD, there was no effect of MNP on wasting. However, among children without clinically significant IHbD,
those who received MNP had a higher final prevalence of wasting
(6·4 %) than those who received placebo (3·6 %).

Effects of micronutrient powder on children’s diarrhoeal
morbidity and effect modification by baseline iron status
and inherited Hb disorders
There was no overall difference in longitudinal diarrhoea
prevalence and diarrhoea incidence between treatment groups
(Table 6). However, IHbD status modified the intervention
effect on diarrhoea prevalence marginally (P = 0·095; Table 4).
Among children with IHbD, those in the MNP group had higher
diarrhoea prevalence compared with those in the placebo group
(1·37 (95 % CI 1·17, 1·59) v. 1·21 (95 % CI 1·04, 1·41)); by contrast
among children without IHbD those who received MNP had a
lower diarrhoea prevalence compared with those in the placebo
group (1·15 (95 % CI 0·95, 1·39) v. 1·37 (95 % CI 1·13, 1·64)).

Discussion
Among young children in the central rural Lao PDR, the anaemia
prevalence and the presence of IHbD were high. Daily provision
of a low-Fe-, high-Zn-containing MNP to young Laotian
children resulted in significantly increased Hb and ferritin and
decreased sTfR concentrations after 9 months of supplementation. The impact on Hb and Fe status indicators was significantly
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Table 3. Baseline Hb concentration, anaemia prevalence, iron status concentrations and anthropometrics by type of inherited Hb disorders (IHbD) among young children participating in the Lao Zinc Study
(Mean values and standard deviations; numbers and percentages; medians and quartiles 1 and 3)
Non-clinically
significant IHbD
Mean

SD

Mean

10·4

105·9

554
109·9

β-Thalassaemia
trait or
homozygous Hb E

Hb E trait

SD

Mean

8·0

107·8

40

SD

Mean

10·0

103·0

603

α- or βThalassaemia
disease

SD

Mean

9·4

93·7

189

SD

P†

26
9·3

259
46·8
473

30
75·0
33

331
54·9
515

140
74·1
154

26
100·0
23

16·6
8·6, 30·1

18·4
12·2, 27·7

18·6
9·5, 33·1

22·0
11·1, 34·1

21·1
12·0, 37·0

166
35·1

8
24·2

169
32·8

44
28·6

6
26·1

8·54
7·14, 10·80

9·38
7·56, 10·58

8·64
7·28, 10·75

9·84
8·56, 12·40

17·31
13·34, 25·43

252
53·3
554

21
63·6
40

289
56·1
603

122
79·2
189

23
100·0
26

<0·001*
<0·001*

0·090

0·338
<0·001*
<0·001*

73·0
–1·58

5·42
1·06

72·3
–1·63

194
35·0
8·38
–1·36

8·36
–1·26

123
22·2

39
7·0

8·35
–1·40

0·87

13·9
–0·55

1·29
0·98

–0·68

8·36
–1·46

1·23
0·95

–0·71

8·21
–1·49

1·64
1·23

0·712
0·635
0·016*

–0·55

1·26

0·606
0·826

1·26
1·08

0·884
0·894
0·331

2
7·7
0·92
0·83

14
7·4

0·039*
0·016*
0·087

11
42·3
0·89

13·8
–0·72

5·50
1·00
14
53·8

12
6·3
0·99
0·87

40
6·6

71·5
–2·08

47
24·9
0·93

13·8
–0·68

5·47
1·02
79
41·8

50
8·3
1·00
0·89

1
2·5

72·8
–1·81

161
26·7

2
5·0
0·95
0·84

26
4·7

1·18
0·96

–0·55

5·42
1·05
236
39·1

10
25·0
0·90

13·8
–0·65

72·7
–1·74

11
27·5
1·28
0·93

–0·74

5·18
0·96

S. Y. Hess et al.

Baseline Hb (n)
Hb (g/l)
Anaemia (Hb < 110 g/l)
n
%
Baseline Fe status‡ (n)
Ferritin (μg/l)
Median
Q1, Q3
Low ferritin (pF < 12 μg/l)
n
%
sTfR (mg/l)
Median
Q1, Q3
High sTfR (sTfR > 8·3 mg/l)
n
%
Baseline anthropometry (n)
Length (cm)
LAZ
Stunting (LAZ < –2 SD)
n
%
Weight (kg)
WAZ
Underweight (WAZ < –2 SD)
n
%
WLZ
Wasting (WLZ < –2 SD)
n
%
MUAC (cm)
MUACZ
Low MUACZ (MUACZ < –2 SD)
n
%

α0-Thalassaemia
trait

13·8
–0·62
3
11·5

pF, plasma ferritin; sTfR, soluble transferrin receptor; LAZ, length-for-age z score; WAZ, weight-for-age z score; WLZ, weight-for-length z score; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z score.
* Statistically significant (P < 0·05).
† P value for bivariate association controlling for child age at enrolment and district.
‡ Fe status indicators adjusted for inflammation.
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Table 4. Significance of effect modification of responses to micronutrient powder (MNP) by baseline Hb and iron status, inherited Hb disorder (IHbD) type and
the presence and absence of IHbD on final study outcomes among young children who received either a low-iron, high-zinc MNP or a placebo powder in the
Lao Zinc Study

Hb
Anaemia
Ferritin†
Low ferritin†
sTfR†
High sTfR†
Length
LAZ
Stunting
Weight
WAZ
Underweight
Weight-for-length
WLZ
Wasting
MUAC
MUACZ
Low MUACZ
Diarrhoea longitudinal
prevalence
Diarrhoea incidence

Baseline
Hb

Baseline
ferritin†

Baseline
sTfR†

IHbD
type‡

Presence/
absence
of IHbD§

0·037*
0·935
0·113
0·158
<0·001*
0·690
0·141
0·082*
0·323
0·508
0·425
0·639
0·582
0·983
0·596
0·038**
0·037**
0·164
0·508

0·012*
0·014*
0·027*
0·166
<0·001*
0·134
0·604
0·624
0·677
0·238
0·407
0·644
0·520
0·285
0·668
0·252
0·280
0·878
0·305

0·152
0·401
0·025*
0·941
<0·001*
0·032**
0·117
0·307
0·882
0·207
0·336
0·629
0·274
0·746
0·615
0·553
0·585
0·215
0·352

0·557
—
0·103
—
0·909
—
0·813
0·789
0·355
0·496
0·664
0·601
0·716
0·676
—
0·175
0·225
—
0·247

0·146
0·409
0·255
0·062*
0·645
0·062*
0·849
0·802
0·786
0·150
0·202
0·970
0·353
0·208
0·019**
0·659
0·693
0·321
0·095*

0·178

0·495

0·669

0·292

0·274

sTfR, soluble transferrin receptor; –, not available because model did not converge; LAZ, length-for-age z score; WAZ, weight-for-age z score; WLZ, weight-for-length z score; MUAC,
mid-upper arm circumference; MUACZ, MUAC z score.
Statistical significance: * P < 0·10, ** P < 0·05.
† Fe status indicators adjusted for inflammation. Continuous outcomes log transformed for analysis.
‡ IHbD types included five categories: α0-thalassaemia trait, β-thalassaemia or homozygous Hb E, Hb E trait, thalassaemia disease, non-clinically significant IHbD.
§ All IHbD were combined into one category (i.e. α- or β-thalassaemia or Hb E) and compared against all cases without clinically significant IHbD.

greater among those with lower Hb and lower Fe status at baseline and those without clinically significant IHbD. MNP had no
overall impact on any of the growth outcomes measured, nor
on the longitudinal diarrhoea burden. However, there was a
trend towards a small adverse effect of MNP on growth (LAZ
and MUAC) among children who were initially non-anaemic,
but not among children who were anaemic. MNP had a small
beneficial impact on longitudinal diarrhoea prevalence among
children without clinically significant IHbD, but a small adverse
effect among children with IHbD.
Although there was a significant effect of MNP on concentrations of Hb and Fe status indicators, and a reduction in the prevalence of Fe deficiency, the 8 % reduction in anaemia prevalence
at end line was only marginally significant. This lack of a significant impact differs from that found in two meta-analyses,
where MNP reduced anaemia by 34 %(3,4), and we have
previously discussed the potential reasons for the present results
elsewhere(16). The MNP in the present study provided additional
micronutrients along with Fe, including folic acid, vitamin B12
and vitamin A; so inadequacy of these nutrients should not have
limited the Hb response to the MNP. It is possible that other
non-nutritional factors such as IHbD, intestinal helminths and
other infections may have contributed to the anaemia burden
in the study population. Indeed, we found highly significant
differences in baseline anaemia prevalence between the IHbD
types as categorised in the present study. Thus, although
IHbD did not modify the Hb response to MNP in the present
analyses, IHbD was associated with an elevated prevalence of
anaemia.

The aforementioned meta-analyses also found an effect of
MNP on the prevalence of Fe deficiency(3) and Fe-deficiency
anaemia(4); however, the meta-analysis by Salam et al.(4) found
no impact of MNP on final serum ferritin concentrations, and de
Regil et al.(3) were unable to determine an impact on ferritin
concentrations due to the low quality of evidence in available
studies. We found that the provision of MNP containing 6 mg
Fe not only decreased the prevalence of low ferritin and high
sTfR concentrations (indicative of Fe deficiency) but also
increased the mean concentrations of ferritin and reduced mean
concentrations of sTfR. As expected, we found that these effects
of MNP on Hb, ferritin and prevalence of anaemia and Fe deficiency were greater among children who had low baseline Hb,
low ferritin or high sTfR concentrations.
Although we did not detect a modifying effect of IHbD on the
impact of MNP on final anaemia prevalence, the presence/
absence of IHbD marginally modified the intervention effect
on the prevalence of low ferritin and high sTfR at end line.
MNP reduced the prevalence of low ferritin and high sTfR in both
children without clinically significant IHbD and those with IHbD,
when all IHbD were combined, but it appeared to have a
stronger effect among children without IHbD. This was
expected, because both ferritin and sTfR are affected not only
by Fe deficiency but also by changes in Fe metabolism and erythropoiesis observed in individuals with IHbD(33). Children with
IHbD tended to have higher ferritin concentrations at baseline
and end line, which is likely due to an increased Fe absorption
observed in some IHbD types(13,15). Similarly, in individuals with
IHbD, sTfR concentrations are frequently elevated due to
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Fig. 2. Effect modification of baseline anaemia and iron status on Hb and iron status at end line among young children who received either a low-iron-, high-zinc-containing micronutrient powder (▪) or a placebo powder ( ). Only selected significant or marginally significant effect modifications are shown; a complete overview of effect
modifications is included in Table 4. Iron status indicators adjusted for inflammation. Continuous outcomes log transformed for analysis. sTfR, soluble transferrin receptor. Values are means, with standard deviations represented by vertical bars.
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Table 5. Effect of a low-iron-, high-zinc-containing micronutrient powder (MNP) on the prevalence of anaemia, iron deficiency and wasting by inherited Hb
disorder (IHbD) type†
(Numbers of participants, percentages, prevalence ratios for comparison values and 95 % confidence intervals)
MNP

N
Anaemia (%) (Hb < 110 g/l)

Low ferritin (%) (pF < 12 μg/l)§

High sTfR (%) (sTfR > 8·3 mg/l)§

Wasting (%) (WLZ < –2

SD)

Non-clinically significant
Hb E trait
β-Thalassaemia trait or
homozygous Hb E
Non-clinically significant
Hb E trait
β-Thalassaemia trait or
homozygous Hb E
Non-clinically significant
Hb E trait
β-Thalassaemia trait or
homozygous Hb E
Non-clinically significant
Hb E trait
β-Thalassaemia trait or
homozygous Hb E

Placebo

Baseline

End line

Baseline

End line

n

n

n

n

%

%

%

%

Minimally
adjusted
comparison

95 % CI‡

IHbD

475 111 48·3 68 29·6 110 44·9 85 34·7
530 158 60·3 101 38·5 134 50·0 108 40·3
167 60 72·3 52 62·7 63 75·0 57 67·9

0·79
0·89
0·96

0·62, 1·01
0·73, 1·10
0·77, 1·18

IHbD

374
420
128

IHbD

IHbD

68 37·0
74 35·9
19 26·8

70 36·8
66 30·8
19 33·3

72 37·9
52 24·3
15 26·3

0·56*
0·83
0·60

0·42, 0·75
0·60, 1·16
0·28, 1·29

374 100 54·3
420 123 59·7
128 56 78·9

72 39·1 100 52·6
89 43·2 114 53·3
43 60·6 48 84·2

94 49·5
95 44·4
45 78·9

0·75*
0·88
0·85

0·61, 0·92
0·73, 1·06
0·68, 1·06

497
537
172

15
15
5

9
14
2

2·87*
0·86
0·70

1·21, 6·83
0·46, 1·63
0·16, 3·11

17 7·2
25 9·4
10 11·9

42 22·8
42 20·4
8 11·3

6·4
5·7
6·0

18
21
2

7·2
7·7
2·4

3·6
5·1
2·4

pF, plasma ferritin; sTfR, soluble transferrin receptor; WLZ, weight-for-length z-score.
* Statistically significant difference between the MNP and the placebo group (P < 0·05).
† Because the model to explore effect modification did not converge for the prevalence of anaemia, low ferritin and high sTfR and wasting, we investigated the impact of MNP on these
prevalence (and the concentrations of the respective indicators) in stratified analyses by those IHbD types, for which we had reasonably large sample sizes.
‡ Adjusted for baseline value, age at enrolment, and regional district.
§ Fe status indicators adjusted for inflammation. Continuous outcomes log transformed for analysis.
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P for interaction = 0·062
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Endline sTfR > 8·3 mg/l (%)

Endline ferritin < 12 μg/l (%)
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P for interaction = 0·062
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Fig. 3. Effect modification of inherited Hb disorder (IHbD) on final iron status among young children who received either a low-iron, high-zinc micronutrient powder ( ) or
a placebo powder ( ). Only significant or marginally significant effect modifications are shown; a complete overview of effect modifications is included in Table 4. Iron
status indicators adjusted for inflammation. Continuous outcomes log transformed for analysis. All IHbD were combined into one category and compared against all
cases without clinically significant IHbD. sTfR, soluble transferrin receptor. Values are means, with standard deviations represented by vertical bars.

increased erythropoiesis(34). Thus, both ferritin and sTfR are
affected by IHbD and, therefore, do not reflect Fe status alone.
This is in agreement with previous findings that different types of
IHbD respond differently to Fe supplementation(35), and it has
been shown that hepcidin concentrations and Fe absorption differ by IHbD type(13,14).
In the present study, we found a modifying effect of initial Hb
status on final LAZ, MUAC and MUACZ in response to MNP. There

was a positive impact on final mean LAZ and final mean MUAC
and MUACZ among initially anaemic children, while MNP was
associated with a small adverse effect on linear growth among
non-anaemic children. Although MNP contained several micronutrients, which could potentially have contributed to this
adverse effect, several previous studies have shown an adverse
effect of Fe on growth among non-anaemic or Fe-replete children.
For example, Fe supplementation resulted in lower weight gain

Downloaded from https://www.cambridge.org/core. Missouri State University, on 07 May 2021 at 17:39:14, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114519001715

Iron status, Hb disorders and micronutrient powder

S. Y. Hess et al.

Fig. 4. Effect modification of inherited Hb disorder (IHbD) and baseline anaemia on selected growth outcomes among young children who received either a low-iron-,
high-zinc-containing micronutrient powder ( ) or a placebo powder ( ). Only selected significant or marginally significant effect modifications are shown; a complete
overview of effect modifications is included in Table 4. All IHbD were combined into one category (i.e. α- or β-thalassaemia or Hb E) and compared against all cases
without clinically significant IHbD. WLZ, weight-for-length z score; LAZ, length-for-age z score; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z score. Values are means, with standard deviations represented by vertical bars.

compared with placebo in young children in Indonesia(36), and
Swedish infants who received Fe supplements from 4 to 9 months
of age gained significantly less in length and head circumference
than those given placebo(37). This latter study also included a
cohort of children in Honduras, where this same effect of reduced
length gain was found only in children who were initially nonanaemic, which is similar to the present results. The overall impact
of supplementary Fe on young children’s growth has been inconsistent(38), and the underlying mechanisms of reduced growth
observed with Fe supplementation in some studies are
unknown(39), but supplementary Fe may be more likely to result
in adverse effects on growth among non-anaemic or Fe-replete
children(37,40,41).
Among the growth outcomes, only final wasting prevalence was
modified by IHbD. When investigating this further, MNP seemed to
slightly increase the final wasting prevalence only among children
without clinically significant IHbD and children with β-thalassaemia
trait or homozygous Hb E, though it did not reach significance in the
latter group. It is known that clinically severe forms of thalassaemia
can result in growth restriction(42,43). Similarly, in the present study,

we found significant differences in baseline length and LAZ, with
the smallest LAZ among children with thalassaemia disease.
However, it is not clear why MNP would adversely affect wasting
among some subgroups of children without clinically significant
IHbD and children with β-thalassaemia trait or homozygous Hb
E, considering that there was no overall effect of MNP on the final
length and final weight; and neither one of these anthropometric
outcomes was modified by IHbD at end line. However, in a recent
Zn dose–response trial of small quantity lipid-based nutrient supplements (SQ-LNS) among young Burkinabe children, final wasting
prevalence was also significantly higher in the group that received
SQ-LNS containing 10 mg Zn for 9 months compared with the children who received SQ-LNS without Zn (13·2 v. 7·2 %)(44). This negative impact of MNP and SQ-LNS containing 10 mg Zn is puzzling,
considering that a meta-analysis of twenty-two studies of preventive Zn supplementation provided as either tablets or syrup, including thirteen studies that provided 10 mg supplemental Zn, found a
small, marginally significant, positive effect of Zn on change in
weight-for-height z score(45). Moreover, in the present study we
found a significantly lower wasting prevalence at end line in the
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Table 6. Effect of a low-iron, high-zinc micronutrient powder (MNP) on diarrhoea incidence and prevalence of young children in the Lao Zinc Study
(Medians, quartiles 1 and 3; numbers of participants; mean values and standard deviations; rate ratios for comparison and 95 % confidence intervals)
MNP
Median
n
Days observed per child
Diarrhoea days per child
Longitudinal diarrhoea prevalence per child‡
Mean

Placebo
Q1,
Q3

Median

841
252

252

SD

246

Diarrhoea episodes per child
Diarrhoea incidence ratio per child§

1
0·86

95 % CI

Fully adjusted†
comparison

95 % CI

1·00

0·86, 1·16

0·96

0·84, 1·14

1·00

0·88, 1·13

1·00

0·88, 1·14

245,
252
0, 4

1

1·50
3·97

Days at risk per child

Minimally adjusted*
comparison

847
238,
252
0, 3

1

Q1,
Q3

1·38
2·70
231,
252
0, 2
3·07

247
1
0·70

236,
252
0, 2
1·25

* Minimally adjusted for baseline value, age at enrolment and regional district.
† Fully adjusted includes adjustments for minimal adjustment variables and potentially for maternal age, height, BMI, and education, child sex, month of enrolment, adequate dietary
diversity at baseline, minimum meal frequency at baseline, Fe-rich foods consumed at baseline, number of children under 5 years in the household, household food insecurity score,
socio-economic index, average adequate dietary diversity, average consumption of Fe-rich foods, and baseline growth status.
‡ Days with diarrhoea in 100 d observed. Diarrhoea defined as 24 h with at least three loose or liquid stools.
§ Episodes of diarrhoea in 100 d at risk of having a diarrhoea episode defined as a period of diarrhoea followed by 2 d diarrhoea free.

group receiving Zn supplements alone (7 mg Zn/d) compared
with the therapeutic Zn supplementation group (20 mg Zn for
10 d during diarrhoea episodes)(16). Thus, it is possible that some
other component of the MPN and SQ-LNS may block the effect of
Zn on wasting prevalence. Further research is needed to understand these effects.
Overall, MNP had no impact on the longitudinal diarrhoea
prevalence or diarrhoea incidence rates in the present study.
Thus, providing an MNP with a higher dose of Zn did not result
in the beneficial impact on diarrhoea observed in randomised
control trials of preventive Zn supplementation provided as tablets or syrups(45–47). This may be due to the Fe contained in MNP.
In a meta-analysis, Mayo-Wilson et al.(48) found a significant beneficial impact of preventive Zn on diarrhoea incidence among
children who received Zn without Fe (risk ratio 0·82 (95 % CI
0·85, 0·89; twenty-two studies)), but this effect was not found
among studies where Fe was given along with Zn (risk ratio
1·00 (95 % CI 0·96, 1·05); ten studies). While we found no benefit
of MNP on diarrhoea, we also found no overall adverse effect of
MNP on diarrhoea. This is in contrast to a cluster randomised trial
among 6- to 18-month-old children in Pakistan, which found that
MNP significantly increased the longitudinal diarrhoea prevalence and incidence of bloody diarrhoea(49). Several other studies also found no difference in diarrhoea or overall morbidity
among children who received MNP compared with a control
group(50–53). However, we found that MNP appeared to have a
small beneficial impact on longitudinal diarrhoea prevalence
among children without clinically significant IHbD and a small
adverse effect among children with IHbD. The magnitude of
the adverse effect on diarrhoea was small and the modifying
effect was only marginally significant. Nevertheless, public
health programmes considering MNP population-based distribution should also strengthen the diarrhoea treatment programme.
The mechanism by which MNP might increase diarrhoea among
children with IHbD is not clear. MNP has been shown to adversely
affect the microbiome in the gut by increasing the abundance of

pathogens and causing intestinal inflammation(54,55), but it is not
known whether this effect would differ by IHbD type.
To our knowledge, this is the first MNP study that investigated
the modifying effects of baseline Fe status and IHbD on various
health outcomes. Strengths of the present study include the randomised double-blind study design, large sample size, frequency
of follow-up, high participation rates and regular training and rigorous supervision of the data collectors. A limitation of the study
is that we were not able to complete assessments of the full set of
IHbD in all children. Although we assessed α0-thalassaemia genes
in all children, other genetic tests were performed primarily
among children with a suspicion of clinically significant IHbD.
In particular, molecular screening for β-thalassaemia mutations
was carried out in children with either Hb A2 > 3·5 % or Hb EF
phenotype, and homozygosity of Hb E was tested in all cases with
Hb EE as well as Hb EF phenotypes. Thus, although
complete diagnosis of all types and variations of IHbD was not
possible, the analytic approach allowed for the detection of all
clinically significant cases of IHbD.
In summary, low-Fe, high-Zn MNP had a beneficial impact on
Hb, ferritin and sTfR concentrations, especially among children
with low initial Hb concentration and Fe status. The MNP had
no overall impact on growth and longitudinal diarrhoea prevalence, but provision of MNP was associated with a small adverse
effect on linear growth among non-anaemic children and on diarrhoea among children with IHbD. The magnitude of observed
adverse effects was small but highlighted subgroups who may
respond adversely to supplemental MNP. The potential risks
and benefits of population-based distribution of MNP must be considered in individual contexts, depending on the prevalence of
anaemia and IHbD.
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